Patents Issued in February 8, 2024
  • Publication number: 20240041792
    Abstract: The present invention relates to a topical composition comprising a cannabinoid, extracellular matrix component or extracellular matrix fragment, and a pharmaceutically acceptable carrier, excipient, diluent, reagent, or combinations thereof, and use thereof in the treatment skin disorders, muscle pain, and arthritic pain.
    Type: Application
    Filed: July 26, 2023
    Publication date: February 8, 2024
    Applicant: TRUETIVA, Inc.
    Inventor: J. Phillip KENNEDY
  • Publication number: 20240041793
    Abstract: The present invention is based on the highly soluble and bioavailable curcuminoid compositions which can be made at a commercial scale with a simple manufacturing process. Thus, the present invention relates to oral compositions comprising a curcuminoid compound, for use in the nutraceutical, pharmaceutical, food or beverage industries and its production methods.
    Type: Application
    Filed: June 8, 2021
    Publication date: February 8, 2024
    Inventor: Mehmet Nevzat PISAK
  • Publication number: 20240041794
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 8, 2024
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Publication number: 20240041795
    Abstract: A cyclic ketone compound can be used the pharmaceutical field, including in the field of perioperative medicine.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 8, 2024
    Inventors: Bowen KE, Jin LIU
  • Publication number: 20240041796
    Abstract: Disclosed is an anti-inflammatory composition containing N-benzyl-N-methyldecan-1-amine or a derivative thereof as an active ingredient. The anti-inflammatory composition contains a compound represented by a following Chemical Formula 1 as an active ingredient. wherein in the Chemical Formula 1, R1 represents hydrogen, fluorine, an alkyl group having 1 to 5 carbon atoms, or an alkoxy group having 1 to 5 carbon atoms, each of R2 and R3 independently represents an alkyl group having 1 to 5 carbon atoms.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 8, 2024
    Applicants: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HaYoung Meditech Inc.
    Inventor: Young Hwa CHUNG
  • Publication number: 20240041797
    Abstract: An auto-injector device includes a pre-filled syringe including a container and a stainless steel needle adhered to the container with at least one of a urethane acrylate adhesive or a urethane methacrylate adhesive. The container is filled with at least 1 mL of a pharmaceutical composition comprising epinephrine, a buffer, and water, where the pharmaceutical composition has a pH ranging between 3 and 4. The auto-injector device also includes a firing mechanism that expels about 0.3 mL of the pharmaceutical composition from the container in less than 0.5 seconds during a single injection.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 8, 2024
    Inventors: Vijay Joguparthi, Rosario LoBrutto
  • Publication number: 20240041798
    Abstract: Provided herein are methods, kits and compositions for the treatment and/or prevention of ovarian cancer through the induction of an immune response against Anti-Mullerian Hormone Receptor, Type II (AMHR2).
    Type: Application
    Filed: September 7, 2023
    Publication date: February 8, 2024
    Inventors: Vincent K. Tuohy, Suparna Mazumder, Justin M. Johnson
  • Publication number: 20240041799
    Abstract: Dietary supplements, nutraceutical compositions, medical foods, animal feeds, and pharmaceutical compositions for treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. A synergistic composition containing a high dose range of agmatine and acceptable salts thereof and in combination with other active ingredients having salutary effects in treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. The composition prepared with excipients and compatible carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solution to facilitate consumption.
    Type: Application
    Filed: March 7, 2023
    Publication date: February 8, 2024
    Inventors: Gad M. Gilad, Varda H. Gilad
  • Publication number: 20240041800
    Abstract: Provided are a metformin inhalation powder aerosol for treating idiopathic pulmonary fibrosis and a preparation method thereof, including following steps: pretreating a metformin raw material to obtain fine powder, and passing the obtained fine powder through a screen with a mesh size of 100-1000 microns by an pendular granulator at a rotating speed of 200 revolutions per minute to obtain soft particle clusters; pre-spheronizing clusters at a vibration frequency of 100-300 hertz to obtain particle clusters, and then rolling the particle clusters on a granulating pan and spheronizing to obtain spherical particle clusters.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 8, 2024
    Inventors: Fangyan WANG, Xiujie LIU, Zhengyang SONG, Xiawei JI, Hang ZHOU, Qingzhen ZHANG, Jie DONG, Kaiqi SHI
  • Publication number: 20240041801
    Abstract: The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of peramivir, cidofovir, or nevirapine and an effective amount of a second antiviral agent. Also provided are methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. Also provided are formulations and methods of delivering the formulations to an individual.
    Type: Application
    Filed: September 14, 2023
    Publication date: February 8, 2024
    Inventor: Dayu TENG
  • Publication number: 20240041802
    Abstract: The present disclosure provides methods, kits, and compositions comprising ?-alethine and one or more immune modulators and methods to determine when they are advantageous. Particular applications include the use of ?-alethine and one or more immune modulators in the treatment of cancer.
    Type: Application
    Filed: June 5, 2023
    Publication date: February 8, 2024
    Inventors: Floyd TAUB, Amanda Guth
  • Publication number: 20240041803
    Abstract: A dosage form of lacosamide and a pharmaceutical dosage form thereof is disclosed. The dosage form includes an extended release portion and optionally an immediate release portion. Also provided are methods of providing extended release of lacosamide and treatment of a neurological or psychiatric disease or condition.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 8, 2024
    Applicant: Shanghai Aucta Pharmaceuticals Co., Ltd.
    Inventors: Shaoqiong Lyu, Shoufeng Li, Xun Zheng, Zhongqin Wang
  • Publication number: 20240041804
    Abstract: The present invention encompasses NHE-1 inhibitors for use in the treatment of coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: August 24, 2021
    Publication date: February 8, 2024
    Inventors: FLORENCE PORTE THOME, CAROLINE KANT MAREDA, CAROLINE DURAND AVALLONE, JIRI MAREDA, SAMEERA ALLIE
  • Publication number: 20240041805
    Abstract: The present disclosure provides pharmaceutical compositions of niclosamide and a protein that may be administered via inhalation These compositions may be used in nebulized, nasal, and inhaler formats. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.
    Type: Application
    Filed: September 17, 2021
    Publication date: February 8, 2024
    Inventors: Hugh D.C. SMYTH, Ashlee BRUNAUGH, Zachary N. WARNKEN, Hyo-Jong SEO
  • Publication number: 20240041806
    Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 8, 2024
    Applicant: Tsubota Laboratory, Inc.
    Inventors: Kazuo Tsubota, Toshihide Kurihara, Shinichi Ikeda, Kiwako Mori, Xiaoyan Jiang
  • Publication number: 20240041807
    Abstract: Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbutyrate may act synergistically in treatment of the urea cycle disorders, in particular embodiments.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Inventors: Juan C. Marini, Sandesh Chakravarthy Sreenath Nagamani
  • Publication number: 20240041808
    Abstract: This invention is directed to a method of preventing ocular neurodegeneration in a subject in need thereof.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 8, 2024
    Inventor: Monica M. JABLONSKI
  • Publication number: 20240041809
    Abstract: The present invention provides compositions and methods for promoting glycogen synthase activity and augmenting glycogen storage capability in muscle tissue and/or liver tissue in a mammal, relating to administration to the mammal of an effective amount of p-a minoisobutyric acid (BAIBA), an analog or derivative thereof, or a pharmaceutically acceptable salt, ester, acid, polymer, analog or derivative thereof.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Mingru WANG, Ronghua YI, Kylin LIAO, Wenbin YU
  • Publication number: 20240041810
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Application
    Filed: March 8, 2023
    Publication date: February 8, 2024
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt
  • Publication number: 20240041811
    Abstract: The present invention relates to methods, compositions, and unit dosage forms useful for selectively modulating mTORC1 activity.
    Type: Application
    Filed: June 29, 2023
    Publication date: February 8, 2024
    Inventors: Steven LEVENTER, Steven D. Targum
  • Publication number: 20240041812
    Abstract: Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.
    Type: Application
    Filed: August 18, 2023
    Publication date: February 8, 2024
    Inventors: Stephen Kirnon, Eric Freedland, Rajagopal V. Sekhar
  • Publication number: 20240041813
    Abstract: This disclosure is directed is directed to compositions and methods for preventing, treating, or ameliorating the symptoms of a viral infection.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 8, 2024
    Inventor: Nicolas G. BAZAN
  • Publication number: 20240041814
    Abstract: The present disclosure provides use of a reagent for detecting retinol metabolites in preparation of a tool for diagnosing and/or treating pneumoconiosis, and relates to the technical field of biomedicine. The present disclosure verifies that retinol metabolism disturbance and all-trans retinoic acid (ATRA) deficiency are closely related to the pathogenesis of pneumoconiosis. Therefore, the present disclosure sets forth use of retinol and ATRA as biomarkers for screening the pneumoconiosis and use thereof in preparation of products related to the diagnosis of the pneumoconiosis; meanwhile, intervention of the pneumoconiosis with the ATRA can effectively delay the progression of the pneumoconiosis. Therefore, the present disclosure first sets forth use of the ATRA as a medicament for treating the pneumoconiosis.
    Type: Application
    Filed: January 19, 2023
    Publication date: February 8, 2024
    Applicant: Institute of Basic Medical Sciences of Chinese Academy of Medical Sciences
    Inventors: Jing WANG, Meiyue SONG, Jiaxin WANG
  • Publication number: 20240041815
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 8, 2024
    Applicant: MBI Distributing
    Inventor: Ned L. Jensen
  • Publication number: 20240041816
    Abstract: Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed.
    Type: Application
    Filed: December 28, 2022
    Publication date: February 8, 2024
    Inventors: Enrique Poradosu, James F. Oliviero, III, Ron Bentsur
  • Publication number: 20240041817
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Application
    Filed: October 13, 2023
    Publication date: February 8, 2024
    Inventors: Katayoun Zomorodi, Herriot Tabuteau
  • Publication number: 20240041818
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Inventor: Christopher U. Missling
  • Publication number: 20240041819
    Abstract: Embodiments include animal feed preparation systems and methods. In an embodiment, a method of administering fine particulates with a total mixed ration includes adding total mixed ration components to a vessel. The method further includes adding the fine particulates and an aqueous composition to the vessel. The method further includes mixing the aqueous composition, the fine particulates, and the total mixed ration together to form an agglomerated total mixed ration. The method further includes providing the agglomerated total mixed ration to an animal. Other embodiments are also included herein.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 8, 2024
    Inventors: Clayton V. McNeff, Larry C. McNeff, Peter G. Greuel, Emily Miller
  • Publication number: 20240041820
    Abstract: A senotherapeutic compound including a synthetic derivative of flavones, according to the formula (I) as indicated below: in which at least two of R2-R8 are H, and the remainder are individually selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.
    Type: Application
    Filed: November 30, 2021
    Publication date: February 8, 2024
    Inventors: Mario CORREALE, Giovanni GAMBERA, Giovanni Mario PITARI, Venera RUSSO
  • Publication number: 20240041821
    Abstract: The present invention relates to an active ingredient and a drug or composition, respectively, for use in reducing pathogenic germs in the human intestine or for use in reducing colonization of the human intestine with pathogenic germs, preferentially for the purpose of preventing, reducing or curing inflammatory diseases or preferentially for the purpose of prophylactic or therapeutic treatment of inflammatory diseases of the human body.
    Type: Application
    Filed: October 1, 2021
    Publication date: February 8, 2024
    Inventors: Michael PLOCH, Ralph PRIES, Karl-Ludwig BRUCHHAGE
  • Publication number: 20240041822
    Abstract: The invention provides a water-soluble composition comprising cannabis extract. The invention also provides methods of producing a water-soluble composition comprising cannabis extract. The invention further provides a solution comprising cannabis extract. Furthermore, the invention provides a frozen composition, a medication, a pharmaceutical composition, and a kit comprising a water-soluble composition comprising cannabis extract.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 8, 2024
    Inventors: Hillary Peckham, Mykola Ianchenko, Joseph Stevens, Keeley Peckham
  • Publication number: 20240041823
    Abstract: A method of treating a microbial infection in a subject comprises administering to a subject in need thereof an effective amount of a composition comprising mycolactone (MLN). A method of preventing a microbial infection in a subject comprises administering to a subject in need thereof an effective amount of a composition comprising mycolactone (MLN).
    Type: Application
    Filed: June 30, 2023
    Publication date: February 8, 2024
    Inventors: MICHAEL DAVID WILSON, SAMUEL KOJO KWOFIE, SETH OSEI ASIEDU, PRAKASHA KEMPAIAH, YASH GUPTA, RAVINDRA V. DURVASULA
  • Publication number: 20240041824
    Abstract: A topical ophthalmic anesthetic composition includes a formulation with an amount of articaine to provide anesthetic properties when applied topically to the eye, and a pH, viscosity, osmolality, dissociation constant, and additives such as antioxidants, buffers, methylcellulose, to achieve efficacy and safety. The composition can contain articaine in amounts of about 4.0% w/v to about 12.0% w/v and have a pH of about pH 3.5 to pH 7.0. The buffer can be borate/mannitol complex obtained from boric acid or salt thereof and D-mannitol. The articaine formulations can achieve adequate anesthesia of the internal aspect of the eye wall by topical application, without the use of an injectable anesthetic. Exemplary implementations of the disclosure include formulations include articaine in an amount of at least 7.0% w/v, where the formulation is an aqueous solution, a gel, an ointment, or in an encapsulated form.
    Type: Application
    Filed: October 17, 2023
    Publication date: February 8, 2024
    Inventor: Martin URAM
  • Publication number: 20240041825
    Abstract: The present invention relates to a pharmaceutical preparation comprising saroglitazar and myristic acid, or a salt or solvate thereof, for use in the treatment of focal segmental glomerulosclerosis (FSGS).
    Type: Application
    Filed: December 3, 2021
    Publication date: February 8, 2024
    Inventor: Paul Perco
  • Publication number: 20240041826
    Abstract: The human body's response to excessive gut bacterial growth is to deny the microbiome of two classes of amino acids. This halts exponential growth; however, the body is also denied their benefit. In the short term, prevention of explosive infection is accomplished. However, this triggers the necessity of removing the needed amino acids from bodily structure for the body to continue. This becomes the resulting long-term decline seen in human aging. This disclosure is methods to extend to the body the benefit of those missing classes of amino acids by providing them in a form less accessible to bacteria. The preferred embodiments claimed in this disclosure work in tandem to treat and to slow aging.
    Type: Application
    Filed: August 8, 2022
    Publication date: February 8, 2024
    Inventor: Rory Powell Blake
  • Publication number: 20240041827
    Abstract: The disclosure provides carbazole derivatives in combination with Collagenase Clostridium histolyticum (CCH), and use thereof for the treatment of fat related conditions.
    Type: Application
    Filed: September 15, 2021
    Publication date: February 8, 2024
    Inventors: Alon BLOOMENFELD, Racheli GUETA, Eran BLAUGRUND
  • Publication number: 20240041828
    Abstract: Disclosed herein are compositions, kits, and methods employing combinations of (a) one or more Nrf2 agonists; and (b) one or more 3CLpro inhibitors, one or more protease inhibitors, and/or one or more N4-hydroxycytidine nucleoside to treat, inhibit, and/or reduce infections and symptoms caused by infection by a virus such as viruses belonging to the Coronaviridae family (e.g., coronaviruses), Orthomyxoviridae family, the Picornaviridae family, and the Pneumoviridae family of viruses.
    Type: Application
    Filed: July 15, 2023
    Publication date: February 8, 2024
    Inventor: Theodoros Kelesidis
  • Publication number: 20240041829
    Abstract: The present invention is directed to compositions comprising a Tryptophol derivative, a 4-Ethyl-Phenol derivative, or a combination thereof, and methods of using same, such as for modulating abundance, diversity, or both, of a microbial population tin a subject in need thereof.
    Type: Application
    Filed: December 23, 2021
    Publication date: February 8, 2024
    Inventors: Raz JELINEK, Orit MALKA, Omry KOREN
  • Publication number: 20240041830
    Abstract: A method of treating cancer, where the biomarkers are predictive of response to PD-1/PD-L1 blockade and GSK-3 inhibition, and which can be used in the method of treatment.
    Type: Application
    Filed: August 4, 2023
    Publication date: February 8, 2024
    Inventors: Wafik S. EL-DEIRY, Kelsey E. HUNTINGTON, Benedito A. CARNEIRO
  • Publication number: 20240041831
    Abstract: The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.
    Type: Application
    Filed: May 9, 2023
    Publication date: February 8, 2024
    Inventors: John R. Falck, Michal L. Schwartzman, Victor Garcia
  • Publication number: 20240041832
    Abstract: Described herein are compositions and methods for the topical administration of various compounds to the eye, in particular to the posterior portion of the eye. Such compositions and methods are useful for treating various disease and disorders, as well as in promoting the general health of the eye.
    Type: Application
    Filed: March 17, 2022
    Publication date: February 8, 2024
    Inventors: Weizhen WANG, David F. WOODWARD, Nonna SNIDER
  • Publication number: 20240041833
    Abstract: The present invention relates to pharmaceutical products and in particular to pharmaceutical combination products. The invention further relates to uses of such products in medical treatment. Embodiments of the invention have been particularly developed as pharmaceutical combination products of a protoparvovirus and an antiviral benzimidazole derivative or a pharmaceutically acceptable salt or prodrug of the benzimidazole derivative for use in the treatment of cancer and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.
    Type: Application
    Filed: December 16, 2021
    Publication date: February 8, 2024
    Inventors: Antonio MARCHINI, Valérie PALISSOT, Tiina MARTTILA, Gian Mario DORE
  • Publication number: 20240041834
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • Publication number: 20240041835
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Nicola Frances BATEMAN, Paul Richard GELLERT, Kathryn Jane HILL
  • Publication number: 20240041836
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Applicant: NEXTGEN BIOSCIENCE CO., LTD.
    Inventors: Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM
  • Publication number: 20240041837
    Abstract: The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPAR? antagonist.
    Type: Application
    Filed: April 21, 2023
    Publication date: February 8, 2024
    Inventors: Nicholas Simon STOCK, Austin Chih-Yu CHEN, Yalda Mostofi BRAVO, Jason Duarte JACINTHO, Jill Melissa BACCEI, Brian Andrew STEARNS, Ryan Christopher CLARK
  • Publication number: 20240041838
    Abstract: Compositions and methods for the treatment of a human subject in need of treatment for a neutrophil-related condition, in particular who has had a stroke or myocardial ischemia reperfusion injury, by administering to the subject a pharmaceutical composition including a compound of Formula 1, wherein the substituents are as described herein, and in particular wherein the compound is 4,4-dimethyl-1-(3-nitrophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-penten-3-one.
    Type: Application
    Filed: July 31, 2023
    Publication date: February 8, 2024
    Inventors: Zhichao Fan, Bruce T. Liang
  • Publication number: 20240041839
    Abstract: Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.
    Type: Application
    Filed: August 11, 2023
    Publication date: February 8, 2024
    Inventors: Jill M. Pulley, Robert R. Lavieri
  • Publication number: 20240041840
    Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Applicant: Areteia Therapeutics, Inc.
    Inventor: Calman Philip PRUSSIN
  • Publication number: 20240041841
    Abstract: Disclosed herein are methods of treating moderate to severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 75 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof, and treating severe asthma of the eosinophilic phenotype in a human subject in need thereof with a daily dose of about 150 mg to about 300 mg of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Applicant: Areteia Therapeutics, Inc.
    Inventor: Calman Philip PRUSSIN